Bio-Rad Laboratories (BIO-B) Accumulated Expenses (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Accumulated Expenses data on file, last reported at $148.4 million in Q1 2026.

• Quarterly Accumulated Expenses fell 5.72% year-over-year to $148.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.4 million (down 5.72% YoY) and the FY2025 annual result came in at $172.3 million, up 38.73% from the prior year.
• Accumulated Expenses slipped to $148.4 million in Q1 2026 per BIO-B's latest filing, from $172.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $194.8 million in Q4 2022 and bottomed at $124.2 million in Q4 2024.
• The 5-year median for Accumulated Expenses is $157.4 million (2025), against an average of $161.4 million.
• The widest annual swing landed in 2022, when Accumulated Expenses slipped 29.68%; it then jumped 38.73% in 2025.
• Tracing BIO-B's Accumulated Expenses over 5 years: stood at $194.8 million in 2022, then fell by 28.18% to $139.9 million in 2023, then declined by 11.22% to $124.2 million in 2024, then surged by 38.73% to $172.3 million in 2025, then decreased by 13.87% to $148.4 million in 2026.
• Per Business Quant, the three latest BIO-B Accumulated Expenses figures stand at $148.4 million (Q1 2026), $172.3 million (Q4 2025), and $182.8 million (Q3 2025).

Peer Comparison